Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)—a randomized phase II trial of the AIO pancreatic cancer group
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
BACKGROUND Data on perioperative chemotherapy in resectable pancreatic cancer (rPDAC) are limited. NEONAX examined perioperative or adjuvant chemotherapy with gemcitabine plus nab-paclitaxel in rPDAC (NCCN-criteria). PATIENTS AND METHODS NEONAX is a prospective, randomized phase II trial with two independent experimental arms. 127 rPDAC-patients in 22 German centers were randomized 1:1 to perioperative (2 pre- and 4 postop. cycles, arm A) or adjuvant (6 cycles, arm B) Gemcitabine (1000mg/m2) and nab-Paclitaxel (125mg/m2) on days 1,8,15 of a 28-day-cycle. RESULTS The primary endpoint was DFS at 18 mo. in the modified ITT-population (R0/R1-resected pts. who started neoadjuvant CTX (A) or adjuvant CTX (B)). The pre-defined DFS rate of 55% at 18mo. was not reached in both arms (A:33.3% [95%CI 18.5-48.1], B:41.4% [95%CI 20.7-62.0]). 90% of patients in arm A completed neoadjuvant treatment, 42% of pts. in arm B started adjuvant chemotherapy. R0-resection-rate was 88% (arm A) and 67% (arm B), respectively. Median OS (ITT-population) as a secondary endpoint was 25.5mo. [95%CI: 19.7-29.7] in arm A and 16.7mo. [95%CI: 11.6-22.2] in the upfront surgery arm. This difference corresponds to a mDFS (ITT) of 11.5mo. [95%CI 8.8-14.5] in arm A and 5.9mo. [95%CI 3.6-11.5] in arm B. Treatment was safe and well tolerable in both arms. CONCLUSIONS The primary endpoint, DFS rate of 55% at 18 months (mITT-population), was not reached in either arm of the trial and numerically favored the upfront surgery arm B. Median OS (ITT-population), a secondary endpoint, numerically favored the neoadjuvant arm A (25.5mo [95%CI: 19.7-29.7]; arm B 16.7mo. [95%CI: 11.6-22.2]). There was a difference in chemotherapy exposure with 90% of patients in arm A completing preoperative chemotherapy and 58% of patients starting adjuvant chemotherapy in arm B. Neoadjuvant/perioperative treatment is a novel option for pts. with resectable PDAC. However, the optimal treatment regimen has yet to be defined.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Versteijne, E., van Dam, J. L., Suker, M., Janssen, Q. P., Groothuis, K., Akkermans-Vogelaar, J. M., Besselink, M. G., Bonsing, B. A., Buijsen, J., Busch, O. R., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02233 · Cited by 786
Cited by
Neoadjuvant therapy for pancreatic cancer
Springfeld, C., Ferrone, C. R., Katz, M. H. G., Philip, P. A., Hong, T. S., Hackert, T., Büchler, M. W., & Neoptolemos, J. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00746-1 · Cited by 377
PFOS and Its Commercial Alternative, 6:2 Cl-PFESA, Induce Multidrug Resistance in Pancreatic Cancer
Hong, J., Du, K., Zhang, W., Jiang, Y., Yu, H., Pan, T., Wu, T., Zhao, L., Du, W., Zheng, S.-S., et al. (2024) · Environmental Science & Technology · doi:10.1021/acs.est.4c08669 · Cited by 16
de Scordilli, M., Michelotti, A., Zara, D., Palmero, L., Alberti, M., Noto, C., Totaro, F., Foltran, L., Guardascione, M., Iacono, D., et al. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104013 · Cited by 7
Metadata
- Authors
- Seufferlein, T., Uhl, W., Kornmann, M., Algül, H., Friess, H., König, A., Ghadimi, M., Gallmeier, E., Bartsch, D. K., Lutz, M. P., Metzger, R., Wille, K., Gerdes, B., Schimanski, C. C., Graupe, F., Kunzmann, V., Klein, I., Geissler, M., Staib, L., Waldschmidt, D., Bruns, C., Wittel, U., Fichtner-Feigl, S., Daum, S., Hinke, A., Blome, L., Tannapfel, A., Kleger, A., Berger, A. W., Kestler, A. M. R., Schuhbaur, J. S., Perkhofer, L., Tempero, M., Reinacher-Schick, A. C., & Ettrich, T. J.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2023-01
- Volume
- 34
- Issue
- 1
- Pages
- 91-100
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W4302774660
- Cited by
- 168
- References
- 2
- FWCI
- 12.87
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)—a randomized phase II trial of the AIO pancreatic cancer group. https://app.cochat.ai/papers/10.1016/j.annonc.2022.09.161
- The paper
- Seufferlein, T., Uhl, W., Kornmann, M., Algül, H., Friess, H., König, A., Ghadimi, M., Gallmeier, E., Bartsch, D. K., Lutz, M. P., Metzger, R., Wille, K., Gerdes, B., Schimanski, C. C., Graupe, F., Kunzmann, V., Klein, I., Geissler, M., Staib, L., . . . Ettrich, T. J. (2023). Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)—a randomized phase II trial of the AIO pancreatic cancer group. Annals of Oncology. https://doi.org/10.1016/j.annonc.2022.09.161
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.